by Pseudomonas Aeruginosa Infection Treatment Market – Vast Scope of Novel Treatment Approach Shows Way for Growth
The appearance of drug-resistant strains of pseudomonas aeruginosa, leading to high mortality rates, have led to a large number of new approaches for the treatment of the associated infection. So much so, infections due to pseudomonas aeruginosa are now considered a public health concern. Meanwhile, increasing antibacterial drug resistance has necessitated research and innovations in the antibacterial field, in general. According to statistics of the Centers for Disease Control and Prevention, in the U.S., each year, more than 2 million infections and 23,000 deaths are associated with bacterial drug resistance.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111938
To address this issue, enormous research and innovation efforts are underway in the antibacterial field. In particular, for pseudomonas aeruginosa, the development of anti-infectives, new antibiotic formulations, and the antivirulence approach are some of the initiatives taken for the fight against the pathogen. Such needs have risen due to real concerns of hospital-acquired infections associated with pseudomonas aeruginosa, especially among critically-ill and immunocompromised patients.
This has prompted several studies to evaluate the factors for the drug resistance of pseudomonas aeruginosa, and potential consequences on mortality. Besides this, limitations of current therapies, potential for alternative drugs, and new therapeutic options for pseudomonas aeruginosa bode well for the pseudomonas aeruginosa treatment infection market. has released a market study publication on the pseudomonas aeruginosa treatment infection market. According to the findings of the pseudomonas aeruginosa treatment infection market is predicted to expand at a notable ~6% CAGR over the forecast period of 2019 to 2027.
However, on the downside, the development of pseudomonas aeruginosa infection treatment faces hindrances as well. Firstly, scientific and technical challenges pertaining to the development of new antibacterial drugs is impeding pharma companies in such pursuits. Besides, the high cost of development of novel antibacterial formulations that are mostly kept in reserve, makes it difficult for companies to recover their investments. Incidence of incorrectly prescribed antibacterial drugs resulting in the rise of resistant bacteria is a bottleneck for the development of pseudomonas aeruginosa infection treatment options.
Characterized as Multidrug-Resistant, Pseudomonas Aeruginosa Draws Attention at Industry Meets
Intrinsically, pseudomonas aeruginosa is resistant to a large number of commercially-available antibiotics. Further, the bacterium displays remarkable capacity in developing resistance against commonly-used antibiotics such as aminoglycosides and carbapenems. Due to this, pseudomonas aeruginosa is often affirmed as multidrug resistant (MDR), which characterizes different patterns of multiple drug resistance of this bacterium.
Displaying MDR characteristics, pseudomonas aeruginosa has gathered attention for discussion at industry meets and medical conferences. A number of posters at the 2018 Infectious Disease (ID) week in San Francisco that shed light on the risk factors and MDR characteristic of pseudomonas aeruginosa is a case in point. Such industry meets usually include discussions of common multipronged approach for pseudomonas aeruginosa. This is increasingly becoming a commonplace treatment strategy due to resistance concerns with the single-agent therapy approach.
Efficacy against Resistant Strains Garners Higher Share for Combination Therapy
Monotherapy and combination therapy are two approaches for pseudomonas aeruginosa infection treatment. Of the two, combination therapy is the mostly used line of treatment due to the multidrug resistant characteristic of pseudomonas aeruginosa. Combination therapy involves a multipronged approach of administering drugs that have been carefully selected for targeting specific molecules. This validates higher share of combination therapy in the pseudomonas aeruginosa infection treatment market.
Among a number of drugs for pseudomonas aeruginosa infection, the aminoglycoside class of drugs are predicted to hold a leading share in the pseudomonas aeruginosa infection treatment market, finds TMR. Clinically, aminoglycosides are highly-potent broad-spectrum antibiotics for the treatment of life-threatening infections. They are a class of antibiotics meant for the treatment of aerobic gram-negative bacilli infections.
Among the key regions in pseudomonas aeruginosa infection treatment market, North America is at the fore, powered by the U.S. In the U.S., a highly efficient healthcare system and favorable reimbursement policies from both, public and private health insurance providers, are fuelling the growth of the pseudomonas aeruginosa infection treatment market.
Pseudomonas Aeruginosa Treatment Infection Market – Winning Imperatives
Uncontrolled Use of Antibiotics Opens Scope for New Line of Treatment
Due to the indiscriminate use of antibiotics for the treatment of pseudomonas aeruginosa infection, the emergence of antibiotic-resistant bacterial strains has rendered this line of treatment almost ineffective. In this scenario, pharma companies are focused on developing a treatment approach for the same. This provides ample white space for players in the pseudomonas aeruginosa infection treatment market to capitalize on.
Extensive R&D & Hefty Investments Boost Development of Novel Therapies
Keen players are investing heavily in R&D for non-antibiotic treatment options. Under this approach, pharma companies are testing novel compounds that bear chemical similarity with antibiotics. A hefty investment by pharma company CARB-X, in January 2019, for a novel antibiotic to treat serious lung infections caused by a slew of gram-negative bacteria, including pseudomonas aeruginosa, is a case in point.
Funding and sponsorships received for R&D is serving to boost such initiatives. For example, in March 2019, pharma company Procarta Biosystems received funding of US$ 2 million from the Novo Holdings Repair Impact Fund for development of novel therapies. These funds are aimed at developing novel therapies for the treatment of complicated urinary tract infections associated with pseudomonas aeruginosa infection.
Pseudomonas Aeruginosa Treatment Infection Market – Competitive Landscape
From a competitive standpoint, the pseudomonas aeruginosa treatment infection market bears a largely consolidated vendor landscape. A large share of the market is held by the top eight players in the pseudomonas aeruginosa treatment infection market.
Savvy players are focused on attaining regulatory milestones prevalent in the pseudomonas aeruginosa infection treatment market in the near future. To attain this, commercial agreements and partnerships with emerging players is a key growth strategy being adopted by these players. Such alliances for the development of anti-infective agents can help distribute the financial burden among partner firms while attaining the desired goals.
Strategic alliances such as mergers & acquisitions and partnerships are useful for the development of expensive drug formulations. Such alliances are useful for the development of anti-infective drugs that involves high cost, due to the long duration of development and high cost of clinical trials. For example, in June 2019, Catalent Inc. purchased Bristol-Myers Squibb’s Italy-based manufacturing facility. This deal will enable Bristol-Myers Squibb to maintain a strategic presence in Italy via the ongoing development and commercialization of new medicines.
Global Pseudomonas Aeruginosa Infection Treatment Market: Overview
The global pseudomonas aeruginosa infection treatment market was valued at ~US$ 1 Bn in 2018, and is projected to reach ~US$ 1.8 Bn by 2027, expanding at a CAGR of ~6% from 2019 to 2027.
The global pseudomonas aeruginosa infection treatment market is driven by the rise in the prevalence of pseudomonas aeruginosa infections such as pneumonia, cystic fibrosis, urinary tract infection, and bloodstream infection, across the globe.
Pseudomonas aeruginosa infection is a major cause of gram-negative infection. It is most common in patients who have been admitted in a hospital for more than 1 week. People with weakened immune systems are more prone to severe pseudomonas infections.
Antibiotics such as aminoglycoside, cephalosporin, carbapenem, and monobactam are the major pseudomonas aeruginosa infection treatment options.
Global Pseudomonas Aeruginosa Infection Treatment Market: Drivers & Restraints
The global pseudomonas aeruginosa infection treatment market is growing at a rapid pace, owing to increase in the population diagnosed with pseudomonas aeruginosa infection, rise in the prevalence of co-morbidities such as pneumonia, cystic fibrosis, urinary tract infection & bloodstream infection, and rich pipeline of pseudomonas aeruginosa infection treatment options.
Rapidly growing antibacterial resistance is one of the major factors anticipated to drive the pseudomonas aeruginosa infection treatment market during the forecast period. According to U.S. Centers for Disease Control and Prevention (CDC) estimates, antibacterial resistance is responsible for over 2 million infections and 23,000 deaths in the U.S. every year.
However, negligible return on investment and inappropriate prescription and patient compliance are anticipated to hamper the growth of the global pseudomonas aeruginosa infection treatment market during the forecast period.
Global Pseudomonas Aeruginosa Infection Treatment Market: Regional Segmentation
Geographically, the global pseudomonas aeruginosa infection treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa.
North America Pseudomonas Aeruginosa Infection Treatment Market
North America accounted for a significant share of the global pseudomonas aeruginosa infection treatment market in 2018. The region is anticipated to continue to dominate the global pseudomonas aeruginosa infection treatment market in the next few years. The presence of a large target population affected by pseudomonas aeruginosa infection and rise in awareness in the U.S. are the major factors for the dominance of the region.
According to a recent study, pseudomonas aeruginosa infection accounts for approximately 51,000 cases in the U.S. every year.
Europe Pseudomonas Aeruginosa Infection Treatment Market
Europe dominated the global pseudomonas aeruginosa infection treatment in 2018, due to the high prevalence of pseudomonas aeruginosa infections such as urinary tract infection, pneumonia, and other hospital-acquired infection. Additionally, major players focusing on the launch of new products for the treatment of pseudomonas aeruginosa infection, and the early availability of new products, fuel the growth of the pseudomonas aeruginosa infection treatment market in Europe.
The pseudomonas aeruginosa infection treatment market in the U.K. is likely to grow at a rapid pace during the forecast period, owing to the high prevalence of pseudomonas aeruginosa infection; around 5,000 people are affected with this disease in the U.K.
Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market
The Pseudomonas aeruginosa infection treatment market in Asia Pacific is projected to expand at a high CAGR during the forecast period. The presence of a large patient pool with nosocomial infections associated with P. aeruginosa in developing countries such as India and China, and increase in antibacterial resistance in developed countries in the region, are anticipated to propel the pseudomonas aeruginosa infection treatment market in the near future.
Global Pseudomonas Aeruginosa Infection Treatment Market: Major Players
Key players operating in the global pseudomonas aeruginosa infection treatment market include
- Allergan plc,
- Teva Pharmaceutical Industries Ltd.,
- Pfizer, Inc.,
- Lupin Pharmaceuticals, Inc.,
- AstraZeneca, Merck & Co., Inc.,
- Bristol-Myers Squibb Co., and
- Janssen Pharmaceuticals, Inc.
Key Questions Answered in the Pseudomonas Aeruginosa Infection Treatment Market Report
- How does the development of antibiotic strains provide scope of growth in the pseudomonas aeruginosa infection treatment market?
- How alliances and partnerships between players are widening the scope of new linen of treatment for pseudomonas aeruginosa infection treatment?
- What are the revenue share projections of key segments under various criteria in the pseudomonas aeruginosa infection treatment market over the forecast period?
- Which segment is likely to register leading revenue until the end of the forecast period in 2027?
- How is the evolving healthcare system in developing countries of Asia Pacific making an impact on the overall pseudomonas aeruginosa infection treatment market?
Pseudomonas Aeruginosa Infection Treatment Market – Segmentation
Medication
- Monotherapy
- Combination Therapy
Drug Class
- Aminoglycoside
- Cephalosporin
- Carbapenem
- Monobactum
- Others
Route of Administration
- Nasal
- Oral
- Intravenous
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111938/2900
